Can-Fite BioPharma (CANF) Net Income - Minority (2013 - 2017)
Can-Fite BioPharma's (CANF) quarterly Net Income - Minority came in at $94000.0 in Q4 2017, up 169.12% YoY from $34929.0 in Q4 2016, and up 214.63% on a QoQ basis from -$82000.0 in Q3 2017.
Can-Fite BioPharma (CANF) Net Income - Minority (2013 - 2017) Analysis & Trends
Can-Fite BioPharma (CANF) has 5 years of Net Income - Minority data on file, last reported at $94000.0 in Q4 2017.
- Quarterly Net Income - Minority rose 169.12% year-over-year to $94000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $94000.0 (up 169.12% YoY) and the FY2017 annual result came in at $94000.0, up 169.12% from the prior year.
- Net Income - Minority advanced to $94000.0 in Q4 2017, from -$82000.0 in the prior quarter.
- In the past five years, Net Income - Minority ranged from a high of $94000.0 in Q4 2017 to a low of -$335000.0 in Q2 2013.
- A 5-year average of -$94687.5 and a median of -$76000.0 in 2016 frame the typical range for Net Income - Minority.
- The widest YoY moves for Net Income - Minority: up 625.0% in 2017, down 23.26% in 2017.
- Tracing CANF's Net Income - Minority over 5 years: stood at -$335000.0 in 2013, then jumped by 50.75% to -$165000.0 in 2014, then slumped by 61.21% to -$266000.0 in 2015, then jumped by 48.87% to -$136000.0 in 2016, then soared by 169.12% to $94000.0 in 2017.
- The last three Net Income - Minority figures came in at $94000.0 (Q4 2017), -$82000.0 (Q3 2017), and -$53000.0 (Q2 2017), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income - Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Can-Fite BioPharma | 2.76 Mn | -8.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 94,000.00 |
| Sep 30, 2017 | -82,000.00 |
| Jun 30, 2017 | -53,000.00 |
| Mar 31, 2017 | 21,000.00 |
| Dec 31, 2016 | -136,000.00 |
| Sep 30, 2016 | -70,000.00 |
| Jun 30, 2016 | -43,000.00 |
| Mar 31, 2016 | -4,000.00 |
| Dec 31, 2015 | -266,000.00 |
| Sep 30, 2015 | -162,000.00 |
| Jun 30, 2015 | -99,000.00 |
| Mar 31, 2015 | -48,000.00 |
| Sep 30, 2014 | -165,000.00 |
| Jun 30, 2014 | -99,000.00 |
| Mar 31, 2014 | -68,000.00 |
| Jun 30, 2013 | -335,000.00 |